Summary

With the expected worldwide rise in all-cause dementia to approximately 152.8 million by the year 2050 and the potential for disease-modifying therapies such as anti-amyloid monoclonal antibodies, there will be an increased demand on neurologists and memory clinics to rapidly identify and stage patients with Alzheimer's disease (AD) and related dementias. While neuropsychological assessment provides information that is essential to the patient and the clinician, substantial barriers remain, including a shortage of trained neuropsychologists, lengthy test batteries and the delayed turnaround of written reports.

AI summaries can be wrong sometimes—always verify important details using the source article.